Exeliom Biosciences is a clinical-stage biotechnology company developing EXL01, a first-in-class oral drug that utilizes the immuno-modulatory properties of the commensal bacterium _Faecalibacterium prausnitzii_ to enhance innate immune responses. The therapy targets dysregulated immunity in conditions such as inflammatory bowel diseases and solid tumor cancers, improving treatment efficacy in these challenging indications.
Funding
$26M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for inflammatory bowel diseases (IBD) and solid tumor cancers often exhibit limited efficacy due to dysregulated immune responses. Existing therapies may fail to adequately modulate the innate immune system, hindering their ability to effectively combat these challenging conditions.
Solution
Exeliom Biosciences is developing EXL01, a first-in-class oral drug leveraging the immuno-modulatory properties of the commensal bacterium _Faecalibacterium prausnitzii_ to enhance innate immune responses. EXL01 aims to restore balance to dysregulated immunity, improving treatment outcomes in IBD, solid tumor cancers, and potentially certain infectious diseases. The drug candidate facilitates resolution of inflammation without broad immunosuppression by promoting a regulatory phenotype in antigen-presenting cells, downregulating pro-inflammatory T cells, and upregulating a specific Treg subpopulation. In immuno-oncology, EXL01 shifts intracellular signaling induced by immune checkpoint inhibitors, upregulating Th1 immunity and creating synergistic anti-tumor effects. EXL01 is currently being evaluated in multiple clinical trials across various indications.
Target Audience
The primary target audience includes patients suffering from inflammatory bowel diseases and solid tumor cancers, as well as healthcare providers specializing in gastroenterology and oncology.
Features
- First-in-class oral drug utilizing a commensal bacterium (_Faecalibacterium prausnitzii_)
- Targets dysregulated immunity in IBD, solid tumor cancers, and infectious diseases
- Modulates the innate immune system to enhance treatment efficacy
- Promotes resolution of inflammation without broad immunosuppression
- Upregulates Th1 immunity and creates synergistic anti-tumor effects in combination with immune checkpoint inhibitors
- Currently in Phase I and Phase II clinical trials across multiple indications, including Crohn's disease, gastric cancer, and non-small cell lung cancer